Applied therapeutics to present baseline data from phase 3 arise-hf study evaluating at-001 at the 2023 easd annual meeting

The ongoing arise-hf phase 3 global clinical trial is evaluating the efficacy of at-001 (caficrestat) on cardiac functional capacity in patients with diabetic cardiomyopathy (dbcm) baseline data from arise-hf shows patients with dbcm exhibit reduced cardiac functional capacity resulting in decreased physical activity new york, sept. 28, 2023 (globe newswire) -- applied therapeutics, inc. (nasdaq: aplt), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced it will participate in a symposium presentation, entitled diabetic cardiomyopathy (dbcm): a severe complication of diabetes, at the 59th european association for the study of diabetes (easd) annual meeting to take place october 2-6, 2023 in hamburg, germany and online.
APLT Ratings Summary
APLT Quant Ranking